Udhayvir Grewal, GI Oncologist at Winship Cancer Institute of Emory University, shared a post by Yuji Uehara, Medical Oncologist at National Cancer Center Hospital, Data Analyst and Researcher at UC San Diego Health on X, adding:
“Genomics is the diagnosis. I sequence every tumor I see in clinic- no matter if there are FDA approved therapies or not.
This is the standard of care. So much that needs to be done to improve access to genomic profiling and also to change the mindset of folks still stuck in the 90s.
The only tumors I don’t readily sequence are low-intermediate grade small bowel NETs.”
Quoting Yuji Uehara‘s post:
“Paradoxical finding in JAMA Network Open:
The ‘academic delay’ likely stems from uncaptured in-house or single-gene testing before CGP in this Flatiron DB, but we should continue advocating for front-line CGP to broaden patient access to clinical trials.”
Title: Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States
Authors: Chadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, Nicolas Sayegh, Micah Ostrowski, Ayana Srivastava, Diya Garg, Tanner Hardy, Ethan G. Murdock, Arshit Narang, Vinay Mathew Thomas, Haoran Li, Benjamin L. Maughan, Soumyajit Roy, Neeraj Agarwal, Umang Swami
Other Articles Featuring Udhayvir Grewal and Yuji Uehara on OncoDaily.
